Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II for Kidney Damage Prevention in Cardiac Surgery
NCT05199493Phase 3Completed
- Sponsor
- Universität Münster
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Angiotensin II in acute kidney injury (AKI) and Vasoplegia (2 arms), sponsored by Universität Münster. Primary endpoint: Kidney damage after cardiac surgery identified by the difference between [TIMP-2]*[IGFBP7] levels at 12 hours. Started Dec 2021; status: completed.
02
Drugs
Angiotensin II
03
Conditions
acute kidney injury (AKI)Vasoplegia
Beyond the preview
Go deeper on NCT05199493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199493.